Coalitions
“The Fight is in Us” Coalition
By teaming up with “The Fight Is In Us” campaign, Survivor Corps joins a coalition of world-leading medical and research institutions, national blood centers, life science companies, technology companies, philanthropic organizations and survivor groups who have come together to support the rapid development of potential new therapies for COVID-19 patients.
Leading Academic Medical Institutions:
National COVID-19 Convalescent Plasma Expanded Access Program led by Mayo Clinic, Michigan State University and Washington University School of Medicine (St. Louis);
Leading Plasma Companies:
Grifols and CoVIg-19 Plasma Alliance,
Founding members: CSL Behring, Takeda, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, Octapharma and Sanquin;
Leading Blood Centers:
AABB, America’s Blood Centers, Blood Centers of America, New York Blood Centers Enterprises and Vitalant;
Healthcare Organizations:
Anthem and Ashfield Healthcare;
Media:
Ad Council
Advisory and Technology Members:
The Bill & Melinda Gates Foundation and The Lasker Foundation (Advisory support); Microsoft Corp. (Technology support: website and plasma bot);
MITRE (Technology support; hosting website and bot); and,Uber Health (offering free, roundtrip Uber rides to plasma centers)
The CoVIg-19 Plasma Alliance
The CoVig-19 Plasma Alliance was formed in April 2020 to help develop a potential plasma-derived therapy for people at risk for serious complications from COVID-19. The Alliance brought together world-leading plasma companies (Co-founders: CSL Behring and Takeda, plus BioPharma Plasma, Biotest, GC Pharma, LFB, National Bioproducts Institute, Octapharma and Sanquin) to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin (H-Ig) medicine intended for the treatment of patients at risk for serious complications from COVID-19. The hyperimmune globulin, known as CoVIg-19, is a high-quality pharmaceutical product that contains purified, consistent and concentrated levels of convalescent antibodies.
This innovative therapy was evaluated in a multi-national Phase 3 clinical trial led by the National Institute of Allergy and Infectious Disease (NIAID) of the U.S. National Institutes of Health (NIH) that completed in March 2021. While results of the clinical trial were not what we had hoped for, we are proud to have accomplished so much within one year, and in the best interests of patient and public health.
